亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

医学 内科学 肺癌 化疗 肿瘤科 危险系数 回顾性队列研究 人口 胃肠病学 置信区间 环境卫生
作者
Mihaela Aldea,Arianna Marinello,M. Duruisseaux,Wael Zrafi,Nicole Conci,Giacomo Massa,Giulio Metro,I. Monnet,Patricia Iranzo,Fabrizio Tabbò,Emilio Bria,Florian Guisier,Damien Vasseur,Colin R. Lindsay,Santiago Ponce-Aix,Sophie Cousin,Fabrizio Citarella,Vincent Fallet,J.N. Minatta,Anna Eisert
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:18 (5): 576-586 被引量:48
标识
DOI:10.1016/j.jtho.2022.12.018
摘要

INTRODUCTION: Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization of this rare population is still incomplete. METHODS: This retrospective multicenter study included patients with any-stage RET positive (RET+) NSCLC from 31 cancer centers. Molecular profiling included DNA/RNA sequencing or fluorescence in situ hybridization analyses. Clinicobiological features and treatment outcomes (per investigator) with surgery, chemotherapy (CT), immune checkpoint blockers (ICBs), CT-ICB, multityrosine kinase inhibitors, and RET inhibitors (RETis) were evaluated. RESULTS: For 218 patients included between February 2012 and April 2022, median age was 63 years, 56% were females, 93% had adenocarcinoma, and 41% were smokers. The most frequent fusion partner was KIF5B (72%). Median tumor mutational burden was 2.5 (range: 1-4) mutations per megabase, and median programmed death-ligand 1 expression was 10% (range: 0%-55%). The most common metastatic sites were the lung (50%), bone (43%), and pleura (40%). Central nervous system metastases were found at diagnosis of advanced NSCLC in 21% of the patients and at last follow-up or death in 31%. Overall response rate and median progression-free survival were 55% and 8.7 months with platinum doublet, 26% and 3.6 months with single-agent CT, 46% and 9.6 months with CT-ICB, 23% and 3.1 months with ICB, 37% and 3 months with multityrosine kinase inhibitor, and 76% and 16.2 months with RETi, respectively. Median overall survival was longer in patients treated with RETi versus no RETi (50.6 mo [37.7-72.1] versus 16.3 mo [12.7-28.8], p < 0.0001). CONCLUSIONS: Patients with RET+ NSCLC have mainly thoracic and bone disease and low tumor mutational burden and programmed death-ligand 1 expression. RETi markedly improved survival, whereas ICB may be active in selected patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4的应助被萧雨墨采纳,获得10
1秒前
5秒前
yc发布了新的文献求助30
5秒前
sunny发布了新的文献求助10
9秒前
piacerance发布了新的文献求助10
9秒前
科研通AI6.4的应助被yc采纳,获得10
19秒前
苗秋实完成签到,获得积分10
20秒前
科研通AI6.2的应助被amiee采纳,获得10
21秒前
科研通AI6.2的应助被萧雨墨采纳,获得50
22秒前
斯文败类的应助被sue采纳,获得150
27秒前
yc完成签到,获得积分10
30秒前
chen完成签到 ,获得积分10
33秒前
34秒前
36秒前
粥里完成签到,获得积分10
37秒前
41秒前
42秒前
43秒前
芳华如梦完成签到,获得积分10
45秒前
sue发布了新的文献求助150
45秒前
orixero的应助被萧雨墨采纳,获得10
46秒前
dart1023发布了新的文献求助10
47秒前
洁净的三娘完成签到 ,获得积分10
51秒前
1分钟前
BLACKCURRY完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
感存算完成签到,获得积分10
1分钟前
共享精神的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
Lucas的应助被科研通管家采纳,获得10
1分钟前
乔舟完成签到 ,获得积分10
1分钟前
orixero的应助被科研通管家采纳,获得10
1分钟前
fantasy的应助被科研通管家采纳,获得10
1分钟前
1分钟前
科研通AI6.3的应助被萧雨墨采纳,获得20
1分钟前
piacerance完成签到,获得积分10
1分钟前
青柳雅春发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190075
求助须知:如何正确求助?哪些是违规求助? 9577208
关于积分的说明 21851965
捐赠科研通 7788198
什么是DOI,文献DOI怎么找? 3436234
关于科研通互助平台的介绍 2559936
邀请新用户注册赠送积分活动 2482810